



## Liberia

### Support for Vaccine: Measles

#### This Decision Letter sets out the Programme Terms of a Programme

This Decision Letter forms part of the Partnership Framework Agreement and together with the Partnership Framework Agreement sets out the Programme Terms of the Programme. Any term used in this Decision Letter but not defined shall have the meaning given to such term in the Partnership Framework Agreement. The English language version of this Decision Letter shall prevail in the case of any conflict with terms expressed in any other language.

---

1. **Country:** Liberia

---

2. **Vaccine grant number:** LBR-M-C-FU

---

3. **Date of Decision Letter<sup>1</sup>:** 22 November 2023

---

4. **Date of the Partnership Framework Agreement (the "PFA"):** 19 August 2013

---

5. **Programme title:** New Vaccine Support (NVS), Measles, Follow-up campaign

---

6. **Requested product presentation and formulation of vaccine:**

M, 10 doses/vial, lyophilised

---

7. **Programme duration<sup>2</sup>:** 2024

---

8. **Annual Amounts:** (subject to the terms of the PFA)

This is the total amount approved by Gavi for the entire duration of the programme. Annual amounts are defined as per section 4.1 of the PFA. The annual amounts are indicative and not limited for use for the specified year. Any requested adjustments to the Annual Amounts will be subject to Gavi approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the Programme. Further, amounts are indicative and are subject to the availability of funds and relevant approvals by the Gavi Board.

	2023	2024	2025	2026	2027	2028	Total
--	------	------	------	------	------	------	-------

<sup>1</sup> This Decision Letter will apply for the programme duration. Gavi will only update this Decision Letter in the event of the following: i) release of future year approvals; ii) adjustments to initial quantities; iii) product price changes or product switches; and/or iv) co-financing amounts.

<sup>2</sup> This is the entire duration of the programme.

Annual Amounts (US\$)	-	407.113	-	-	-	-	407.113
-----------------------	---	---------	---	---	---	---	---------

**9. Vaccine introduction grant:**

Not applicable

**10. Product switch grant:**

Not applicable

**11. Indicative annual amounts:** (subject to the terms of the PFA)

Gavi Support	- 2023	2024		2025		2026		2027		2028	
		Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)
M, 10 doses/vial, lyophilised		823.500	321.165	-	-	-	-	-	-	-	-
Syringe, A-D 0.5ml		832.600	33.304	-	-	-	-	-	-	-	-
Syringe, Re-constitution		92.500	4.625	-	-	-	-	-	-	-	-
Safety Box		9.250	5.273	-	-	-	-	-	-	-	-
Freight costs - doses		1	32.940	-	-	-	-	-	-	-	-
Freight costs - devices		1	9.806	-	-	-	-	-	-	-	-
<b>Total amounts (US\$)</b>	-		<b>407.113</b>								

**12. Procurement agency:** UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

**13. Self-procurement:**

Not applicable

#### 14. Co-financing obligations (indicative)<sup>3</sup>:

According to the co-financing policy, the Country falls within the group: <b>Initialself-financing</b>										
Co-Finance Obligation	2024		2025		2026		2027		2028	
	Material	Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)	Total Cost (US\$)
M, 10 doses/vial, lyophilised	17.000	6.630	-	-	-	-	-	-	-	-
Freight costs - doses	1	680	-	-	-	-	-	-	-	-
<b>Total Co-Financing (\$USD) expected</b>		<b>7.310</b>		-		-		-		-

#### 15. Operational support for campaigns:

Year	Grant number	Amount (US\$)
2018	LBR-M-C-FU-OPS-MOH	424.187
2024	LBR-M-C-FU-OPS	491.952

#### 16. Additional Reporting Requirements:

Reports and other information :	Due dates
To enable the annual release of purchase orders, Country shall report closing stock levels by 31 <sup>st</sup> March of each calendar year. <sup>4</sup>	31 March
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

<sup>3</sup> Gavi may adjust the outlined co-financing obligations based on the corresponding actual dose shipments to the country. Any over/under co-financed doses/amounts will be settled in subsequent payments.

<sup>4</sup> Reporting requirements are subject to change. Countries may be required to submit quarterly or monthly stock reports. Country will be notified of updated reporting requirements separately.

To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points.	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool.
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign.	Within 3 months of end of campaign.
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign.	As soon as available.

**17. Financial clarifications:**


Not applicable

**18. Other conditions:**

As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

	2024	2025	2026	2027	2028
Minimum number of doses to be financed from domestic resources	798.100	-	-	-	-
Minimum amount to be financed from domestic resources (US\$)	336.813	-	-	-	-

DocuSigned by:


  
 BE4B434378DD46E...
   
 colette selman

23/11/2023